

THIRD BASE PROSPECTUS SUPPLEMENT

Morgan Stanley

(incorporated under the laws of the State of Delaware in the United States of America)

BASE PROSPECTUS FOR THE ISSUANCE OF NOTES, SERIES A AND SERIES B UNDER THE REGULATION S PROGRAM FOR THE ISSUANCE OF NOTES, SERIES A AND B, WARRANTS AND CERTIFICATES

Morgan Stanley (the “**Issuer**”) has prepared this third base prospectus supplement (the “**Third Base Prospectus Supplement**”) to supplement and be read in conjunction with the base prospectus dated 21 July 2025 of Morgan Stanley (as supplemented by the first supplement to the base prospectus dated 13 August 2025 and the second supplement to the base prospectus dated 21 October 2025, the “**Base Prospectus**”) relating to the Regulation S Program for the Issuance of Notes, Series A and Series B, Warrants and Certificates.

This Third Base Prospectus Supplement has been approved by the Luxembourg *Commission de Surveillance du Secteur Financier* (the “**CSSF**”), as competent authority under Regulation (EU) 2017/1129 (the “**Prospectus Regulation**”) and constitutes a supplement for the purposes of Article 23(1) of the Prospectus Regulation.

The CSSF only approves this Third Base Prospectus Supplement as meeting the standard of completeness, comprehensibility and consistency imposed by the Prospectus Regulation and the CSSF gives no undertaking as to the economic and financial soundness of any transaction or the quality or solvency of the Issuer. Such approval should not be considered as an endorsement of the Issuer or the quality of the Notes that are the subject of this Third Base Prospectus Supplement.

This Third Base Prospectus Supplement has also been approved by the Luxembourg Stock Exchange pursuant to the rules and regulations of the Luxembourg Stock Exchange with respect to Exempt Notes for the purpose of providing information with regard to the Issuer for the purpose of listing Notes on the Official List and admitting to trading on the Euro MTF market of the Luxembourg Stock Exchange. The Euro MTF market is not a regulated market for the purposes of MiFID II. **The CSSF has neither approved nor reviewed information contained in this Third Base Prospectus Supplement in connection with the issue of any Exempt Notes.**

Unless otherwise defined in this Third Base Prospectus Supplement, terms defined in the Base Prospectus shall have the same meaning when used in this Third Base Prospectus Supplement. To the extent that there is any inconsistency between any statement in, this Third Base Prospectus Supplement and any other statement in, or incorporated by reference in, the Base Prospectus, the statements in this Third Base Prospectus Supplement will prevail.

The purpose of this Third Base Prospectus Supplement is to:

- (a) incorporate the Registration Document of Morgan Stanley, Morgan Stanley & Co. International plc, Morgan Stanley B.V., Morgan Stanley Finance LLC and Morgan Stanley Europe SE dated 14 November 2025 (the “**2025 Registration Document**”) by reference into the Base Prospectus, as set out in “Part A” of this Third Base Prospectus Supplement;
- (b) disclose the publication by Morgan Stanley of its Quarterly Report on Form 10-Q dated 3 November 2025 for the quarterly period ended 30 September 2025 (the “**Morgan Stanley November 2025 Form 10-Q**”);
- (c) incorporate by reference the Morgan Stanley November 2025 Form 10-Q into the Base Prospectus, as set out in “Part A” of this Third Base Prospectus Supplement;
- (d) make certain consequential amendments to the “*Risk Factors Relating to the Notes*” section in the Base Prospectus pursuant to the publication of the 2025 Registration Document, as set out in “Part B” of this Third Base Prospectus Supplement;
- (e) make certain consequential amendments to the “*Selected Financial Information of Morgan Stanley*” section in the Base Prospectus pursuant to the publication of the Morgan Stanley November 2025 Form 10-Q, as set out in “Part C” of this Third Base Prospectus Supplement; and

- (f) make certain consequential amendments to the “*General Information*” section in the Base Prospectus pursuant to the publication of the 2025 Registration Document and the Morgan Stanley November 2025 Form 10-Q, as set out in “Part D” of this Third Base Prospectus Supplement.

In accordance with Article 23.2 of the Prospectus Regulation, investors who have agreed to purchase or subscribe for, or have applied to purchase or subscribe for, any Notes prior to the publication of this Third Base Prospectus Supplement and where Notes had not yet been delivered to the investors at the time when the significant new factor, material mistake or material inaccuracy arose or was noted, shall have the right, exercisable within three working days following the date of publication of this Third Base Prospectus Supplement, to withdraw their acceptances or applications by notice in writing to the relevant Issuer or Manager, as the case may be. The final date within which such right of withdrawal must be exercised is 24 November 2025.

Save as disclosed in this Third Base Prospectus Supplement, no significant new factor, material mistake or inaccuracy relating to information included in the Base Prospectus has arisen since the publication of the second supplement to the Base Prospectus dated 21 October 2025.

Morgan Stanley accepts responsibility for the information contained in this Third Base Prospectus Supplement. To the best of the knowledge and belief of Morgan Stanley, the information contained in this document is in accordance with the facts and does not omit anything likely to affect the import of such information.

This Third Base Prospectus Supplement, 2025 Registration Document and the Morgan Stanley November 2025 Form 10-Q are available for viewing, and copies may be obtained from, the offices of the Issuer and the Paying Agents and are available on Morgan Stanley’s website at <https://sp.morganstanley.com/EU/Documents> and on the website of the Luxembourg Stock Exchange at www.luxse.com.

The 2025 Registration Document is available on Morgan Stanley’s website at <https://sp.morganstanley.com/download/prospectus/afe6f6cc-6b47-44a2-ac92-dfc8ad86d2d1/>.

The Morgan Stanley November 2025 Form 10-Q is available on Morgan Stanley’s website at <https://sp.morganstanley.com/download/prospectus/232e31a9-c34f-4052-9898-c9e387c8adb8>.

19 November 2025

MORGAN STANLEY

CONTENTS

	Page
PART A – INCORPORATION BY REFERENCE	4 – 5
PART B – AMENDMENTS TO THE “ <i>RISK FACTORS RELATING TO THE NOTES</i> ” SECTION	6
PART C- AMENDMENT TO THE “SELECTED FINANCIAL INFORMATION OF MORGAN STANLEY” SECTION	7
PART C – AMENDMENTS TO THE “ <i>GENERAL INFORMATION</i> ” SECTION	8

PART A – INCORPORATION BY REFERENCE

This Third Base Prospectus Supplement incorporates by reference the 2025 Registration Document and the Morgan Stanley November 2025 Form 10-Q into the Base Prospectus, and the information incorporated by reference must be read in conjunction with the cross-reference table below which supplements the section titled “*Incorporation by Reference*” contained on pages 34 to 41 of the Base Prospectus.

The following document and/or information shall be deemed to be incorporated by reference in, and to form part of, the Base Prospectus:

Document filed	Information incorporated by reference	Page(s)
1. Registration Document of Morgan Stanley, Morgan Stanley & Co. International plc, Morgan Stanley B.V., Morgan Stanley Finance LLC and Morgan Stanley Europe SE dated 14 November 2025 https://sp.morganstanley.com/download/prospectus/afe6f6cc-6b47-44a2-ac92-dfc8ad86d2d1/	(1) Risk Factors (excluding the section headed “ <i>Risks relating to MSI plc, MSBV, MSFL and MSESE</i> ”)	1 – 21
	(2) Availability of the Documents	35
	(3) Description of Morgan Stanley	36 – 57
	(4) Subsidiaries of Morgan Stanley as of 2 October 2025	76
	(5) Index of Defined Terms	77
2. Morgan Stanley November 2025 Form 10-Q https://sp.morganstanley.com/download/prospectus/232e31a9-c34f-4052-9898-c9e387c8adb8	(1) Management’s Discussion and Analysis of Financial Condition and Results of Operations	4 – 27
	(2) Quantitative and Qualitative Disclosures about Risk	28 – 37
	(3) Report of Independent Registered Public Accounting Firm	38
	(4) Consolidated Financial Statements and Notes	39-76
	(i) Consolidated Income Statement (Unaudited)	39
	(ii) Consolidated Comprehensive Income Statement (Unaudited)	39
	(iii) Consolidated Balance Sheet (Unaudited at 30 September, 2025)	40
	(iv) Consolidated Statement of Changes in Total Equity (Unaudited)	41
	(v) Consolidated Cash Flow Statement (Unaudited)	42
	(vi) Notes to Consolidated Financial Statements (Unaudited)	43 – 76
	(5) Financial Data Supplement (Unaudited)	77
	(6) Glossary of Common Terms and Acronyms	78
	(7) Controls and Procedures	79

(8)	Legal Proceedings	79
(9)	Unregistered Sales of Equity Securities and Use of Proceeds	79
(10)	Other Information	79
(11)	Signatures	79

Any non-incorporated parts of a document referred to herein, which for the avoidance of doubt are not listed in the cross-reference list above, are either deemed not relevant for an investor or are otherwise covered elsewhere in the Base Prospectus.

PART B – AMENDMENTS TO THE “*RISK FACTORS RELATING TO THE NOTES*” SECTION

1. The second paragraph on page 5 of the Base Prospectus shall be deemed to be deleted in its entirety and the following substituted therefor:

“Prospective investors should consider the section entitled “*Risk Factors*” at pages 1 to 21 of the Registration Document dated 14 November 2025 (the “**2025 Registration Document**”) referred to in the section entitled “Incorporation by Reference” in this Base Prospectus and the factors described below and consult with their own professional advisers, if they consider it necessary. The Issuer believes that such factors represent the principal risks inherent in investing in Notes issued pursuant to this Base Prospectus but the inability of the Issuer to pay interest, principal or other amounts on or in connection with any Notes may occur for other reasons, which may not be considered significant risks by the Issuer based on information currently available to it or which it may not currently be able to anticipate. The Issuer and Morgan Stanley & Co. International plc, as Distribution Agent, as well as any other affiliate involved in the issuance, offer or sale of the Notes, each disclaim any responsibility to advise prospective purchasers of any matters arising under the laws of the country in which they reside that may affect the purchase of, or holding of, or the receipt of payments on, the Notes. These persons should consult their own legal and financial advisers concerning these matters. This section describes generally the most significant risks of investing in Notes linked to one or more underlyings such as interest rates, swap rates and inflation indices. Each investor should carefully consider whether the Notes, as described herein and in the applicable Final Terms or Pricing Supplement, are suited to its particular circumstances before deciding to purchase any Notes.”

2. The Risk Factor entitled “*Risks relating to the financial situation of Morgan Stanley*” on page 6 of the Base Prospectus shall be deemed to be deleted in its entirety and the following substituted therefor:

“A description of the risks relating to the financial situation of Morgan Stanley that may affect the ability of the Issuer to fulfil its obligations under the Notes are set out in the section entitled “*Risks relating to the financial situation of Morgan Stanley*” on page 1 to 5 of the 2025 Registration Document.”

3. The Risk Factor entitled “*Risks relating to the operation of Morgan Stanley’s business activities*” on page 6 of the Base Prospectus shall be deemed to be deleted in its entirety and the following substituted therefor:

“A description of the risks relating to the operation of Morgan Stanley's business activities that may affect the ability of the Issuer to fulfil its obligations under the Notes are set out in the section entitled “*Risks relating to the operation of Morgan Stanley's business activities*” on pages 5 to 9 of the 2025 Registration Document.”

4. The Risk Factor entitled “*Legal, regulatory and compliance risk*” on page 6 of the Base Prospectus shall be deemed to be deleted in its entirety and the following substituted therefor:

“A description of legal, regulatory and compliance risks that may affect the ability of the Issuer to fulfil its obligations under the Notes are set out in the section entitled “*Legal, regulatory and compliance risk*” on pages 9 to 13 of the 2025 Registration Document.”

5. The Risk Factor entitled “*Other risks relating to Morgan Stanley’s business activities*” on page 6 of the Base Prospectus shall be deemed to be deleted in its entirety and the following substituted therefor:

“A description of other risks relating to Morgan Stanley's business activities that may affect the ability of the Issuer to fulfil its obligations under the Notes are set out in the section entitled “*Other risks relating to Morgan Stanley's business activities*” on pages 15 to 21 of the 2025 Registration Document.”

PART C – AMENDMENT TO THE “*SELECTED FINANCIAL INFORMATION OF MORGAN STANLEY*” SECTION

The section titled “*Selected Financial Information of Morgan Stanley*” on page 31 of the Base Prospectus shall be deemed to be deleted in its entirety and the following substituted therefor:

“SELECTED FINANCIAL INFORMATION OF MORGAN STANLEY

This section contains selected financial information of Morgan Stanley relating to the years ended 31 December 2023 and 31 December 2024 and the nine months ended 30 September 2024 and 30 September 2025.

The information in respect of the years ended 31 December 2023 and 31 December 2024 set out below is derived from the audited financial statements included in Morgan Stanley’s Annual Reports on Form 10-K for the year ended 31 December 2024.

The information in respect of the nine months ended 30 September 2024 and 30 September 2025 set out below is derived from the unaudited financial statements included in Morgan Stanley’s Quarterly Reports on Form 10-Q for the quarterly periods ended 30 September 2024 and 30 September 2025, respectively.

Consolidated Balance Sheet (U.S.\$ in millions)	At 31 December 2024	At 31 December 2023	At 30 September 2025 (unaudited)	At 30 September 2024 (unaudited)
Total assets	1,215,071	1,193,693	1,364,806	1,258,027
Total liabilities and equity	1,215,071	1,193,693	1,364,806	1,258,027

Consolidated Income Statement (U.S.\$ in millions)	At 31 December 2024	At 31 December 2023	Nine months ended 30 September 2025 (unaudited)	Nine months ended 30 September 2024 (unaudited)
Net revenues	61,761	54,143	52,755	45,538
Income before provision for income taxes	17,596	11,813	16,194	12,690
Net income	13,529	9,230	12,601	9,805

PART D – AMENDMENTS TO THE “GENERAL INFORMATION” SECTION

1. Sub-paragraph (d) under the heading “*Documents available*” on page 214 of the Base Prospectus shall be deemed to be deleted in its entirety and the following substituted therefor:

“(d) Morgan Stanley's Annual Report on Form 10-K for the year ended 31 December 2024, Morgan Stanley's Current Reports on Form 8-K dated 11 April 2025, 16 July 2025 and 15 October 2025, Morgan Stanley's Quarterly Reports on Form 10-Q for the quarterly periods ended 31 March 2025, 30 June 2025 and 30 September 2025 and Morgan Stanley's Proxy Statement dated 4 April 2025;”

2. The second paragraph in the section titled “*No material adverse change in prospects and no significant change in financial performance and financial position*” on page 215 of the Base Prospectus shall be deemed to be deleted in its entirety and the following substituted therefor:

“There has been no significant change in the financial performance and the financial position of Morgan Stanley and its consolidated subsidiaries since 30 September 2025, the date of the last published interim (unaudited) financial statements of Morgan Stanley.”

3. The section titled “*Legal and arbitration proceedings*” on page 215 of the Base Prospectus shall be deemed to be deleted in its entirety and the following substituted therefor:

“*Legal and arbitration proceedings*”

Save as disclosed in:

- (a) the paragraphs under the heading “Contingencies” under the heading “14. Commitments, Guarantees and Contingencies” in “Notes to Consolidated Financial Statements” at pages 124 to 127 and the section titled “Legal Proceedings” at page 154 of Morgan Stanley’s Annual Report on Form 10-K for the year ended 31 December 2024;
- (b) the paragraphs under the heading “Contingencies” under the heading “13. Commitments, Guarantees and Contingencies” in “Notes to Consolidated Financial Statements (Unaudited)” at pages 60 to 63 and the section titled “Legal Proceedings” at page 75 of Morgan Stanley’s Quarterly Report on Form 10-Q for the quarterly period ended 31 March 2025;
- (c) the paragraphs under the heading “Contingencies” under the heading “13. Commitments, Guarantees and Contingencies” in “Notes to Consolidated Financial Statements (Unaudited)” at pages 63 to 66 and the section titled “Legal Proceedings” at page 78 of Morgan Stanley’s Quarterly Report on Form 10-Q for the quarterly period ended 30 June 2025;
- (d) the paragraphs under the heading “Contingencies” under the heading “13. Commitments, Guarantees and Contingencies” in “Notes to Consolidated Financial Statements (Unaudited)” at pages 63 to 67 and the section titled “Legal Proceedings” at page 79 of Morgan Stanley’s Quarterly Report on Form 10-Q for the quarterly period ended 30 September 2025; and
- (e) the section entitled “Legal Proceedings and Contingencies” at Part 7 of the section entitled “Description of Morgan Stanley” at pages 53 to 54 of the 2025 Registration Document (as supplemented from time to time),

other than those disclosed in the audited financial statements or the interim (unaudited) financial statements, there are no, nor have there been, any governmental, legal or arbitration proceedings involving Morgan Stanley (including any such proceedings which are pending or threatened of which Morgan Stanley is aware) during the 12-month period before the date of the Third Base Prospectus Supplement which may have, or have had in the recent past, a significant effect on the financial position or profitability of Morgan Stanley.”